Release of TGFβig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1553-1562

  Holmberg, Chris ^a   Quante, Michael ^b   Steele, Islay ^a   Kumar, Jothi Dinesh ^a   Balabanova, Silviya ^a   Duval, Cedric ^a   Czepan, Matyas ^c   Rakonczay, Zoltan ^c   Tiszlavicz, Laszlo ^c   Nemeth, Istvan ^c   Lazar, Gyorgy ^c   Simonka, Zsolt ^c   Jenkins, Rosalind ^a   Hegyi, Peter ^c   Wang, Timothy C ^d   Dockray, Graham J ^a   Varro, Andrea ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF SZEGED   (Hungary)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEOME; STROMAL CELL DERIVED FACTOR 1;

ADJACENT TISSUE MYOFIBROBLAST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER ASSOCIATED MYOFIBROBLAST; CANCER CELL; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MOUSE; MYOFIBROBLAST; NONHUMAN; NORMAL TISSUE MYOFIBROBLAST; PRIORITY JOURNAL; PROTEOMICS; STOMACH CANCER; SURVIVAL TIME; TRANSFORMING GROWTH FACTOR BETA INDUCED GENE H3; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MYOFIBROBLASTS; STOMACH; TRANSFORMING GROWTH FACTORS;

EID: 84865322867     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs180     Document Type: Article

References (48)

1. Bissell,M.J. et al. (2001) Putting tumours in context. Nat. Rev. Cancer, 1, 46-54.
2. Tlsty,T.D. et al. (2006) Tumor stroma and regulation of cancer development. Annu. Rev. Pathol., 1, 119-150.
3. Saadi,A. et al. (2010) Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc. Natl. Acad. Sci. U.S.A., 107, 2177-2182.
4. Tuxhorn,J.A. et al. (2002) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res., 8, 2912-2923.
5. Kalluri,R. et al. (2006) Fibroblasts in cancer. Nat. Rev. Cancer, 6, 392-401.
6. Bhowmick,N.A. et al. (2004) Stromal fibroblasts in cancer initiation and progression. Nature, 432, 332-337.
7. Allinen,M. et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 6, 17-32.
8. Finak,G. et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med., 14, 518-527.
9. Farmer,P. et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med., 15, 68-74.
10. Hagglof,C. et al. (2010) Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS One, 5, e10747.
11. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
12. Erez,N. et al. (2010) Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaBdependent manner. Cancer Cell, 17, 135-147.
13. Crawford,Y. et al. (2009) PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell, 15, 21-34.
14. Orimo,A. et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121, 335-348.
15. Powell,D.W. et al. (2005) Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am. J. Physiol. Gastrointest. Liver Physiol., 289, G2-G7.
16. Jiang,L. et al. (2008) Global hypomethylation of genomic DNA in cancerassociated myofibroblasts. Cancer Res., 68, 9900-9908.
17. Peek,R.M., Jr. et al. (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer, 2, 28-37.
18. Kamangar,F. et al. (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 24, 2137-2150.
19. Correa,P. et al. (1994) Gastric cancer. Cancer Surv., 19-20, 55-76.
20. Weis,V.G. et al. (2009) Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer, 12, 189-197.
21. Wroblewski,L.E. et al. (2003) Stimulation of MMP-7 (matrilysin) by Helicobacter pylori in human gastric epithelial cells: role in epithelial cell migration. J. Cell Sci., 116, 3017-3026.
22. Hemers,E. et al. (2005) Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: implications for epithelial-mesenchymal signaling. Cancer Res., 65, 7363-7369.
23. McCaig,C. et al. (2006) The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori. Gastroenterology, 130, 1754-1763.
24. Houghton,J. et al. (2004) Gastric cancer originating from bone marrowderived cells. Science, 306, 1568-1571.
25. Quante,M. et al. (2011) Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell, 19, 257-272.
26. Skonier,J. et al. (1992) cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol., 11, 511-522.
27. Billings,P.C. et al. (2002) The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin. J. Biol. Chem., 277, 28003-28009.
28. Skonier,J. et al. (1994) beta ig-h3: a transforming growth factor-betaresponsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol., 13, 571-584.
29. Zhang,Y. et al. (2009) TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res., 69, 37-44.
30. Ahmed,A.A. et al. (2007) The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell, 12, 514-527.
31. Tang,J. et al. (2007) BetaIg-h3 is involved in the HAb18G/CD147-mediated metastasis process in human hepatoma cells. Exp. Biol. Med. (Maywood), 232, 344-352.
32. Ma,C. et al. (2008) Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev., 22, 308-321.
33. Sobin,L.H. et al. (2009) TNM Classification of Malignant Tumours. Wiley-Blackwell, Chichester.
34. Varro,A. et al. (2002) Gastrin-cholecystokinin(B) receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor. Gut, 50, 827-833.
35. Varro,A. et al. (2004) Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis. Cancer Res., 64, 1695-702.
36. Pho,M. et al. (2008) Cofilin is a marker of myofibroblast differentiation in cells from porcine aortic cardiac valves. Am. J. Physiol. Heart Circ. Physiol., 294, H1767-H1778.
37. Kraman,M. et al. (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330, 827-830.
38. Desmouliere,A. et al. (2004) The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int. J. Dev. Biol., 48, 509-517.
39. Bissell,M.J. et al. (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med., 17, 320-329.
40. Xu,B.J. et al. (2010) Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts. Proteomics, 10, 2458-2470.
41. Kannabiran,C. et al. (2006) TGFBI gene mutations in corneal dystrophies. Hum. Mutat., 27, 615-625.
42. Thapa,N. et al. (2007) TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int. J. Biochem. Cell Biol., 39, 2183-2194.
43. Irigoyen,M. et al. (2010) TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol. Cancer, 9, 130.
44. Becker,J. et al. (2006) Keratoepithelin suppresses the progression of experimental human neuroblastomas. Cancer Res., 66, 5314-5321.
45. Wen,G. et al. (2011) TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells. Cancer Lett., 308, 23-32.
46. Zhao,Y. et al. (2006) Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol. Carcinog., 45, 84-92.
47. Ween,M.P. et al. (2011) Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int. J. Cancer, 128, 1570-1584.
48. Beattie,J. et al. (2010) Cross-talk between the insulin-like growth factor (IGF) axis and membrane integrins to regulate cell physiology. J. Cell Physiol., 224, 605-611.